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ABSTRACT
Coccinia grandis (L.) Voigt (Cucurbitaceae), occurs throughout the world and has intensive popular use in
the treatment of infections. The main aim of the present work was to investigate the antidiabetic effects of aqueous
extracts of leaves of C. grandis obtained by Decoction method. Graded doses of the aqueous extract were
administered to normal and experimental diabetic rats for 10 days. Significant (p < 0.05) reduction in fasting blood
glucose levels were observed in the normal as well as in the treated diabetic animals. Serum insulin levels were not
stimulated in the animals treated with the extract. The changes in body weight, serum lipid profiles, liver glycogen
levels were assessed in the extract treated diabetic rats and compared with diabetic control and normal animals.
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INTRODUCTION
Diabetes mellitus (DM) is a serious health problem with high rates of incidence and mortality. DM is
characterized by elevated plasma glucose concentrations resulting from insufficient insulin, insulin resistance or both
leading to metabolic abnormalities in carbohydrates, lipids and proteins (Hernandez-galicia et al., 2002). According
to the World Health Organization, more than 70% of the world’s population must use traditional medicine to satisfy
their principal health needs (Farnsworth et al., 1985). A great number of medicinal plants used in the control of the
DM have been reported (Baily  & Day 1989; Marles & Farnsworth, 1994). However these plants represent
alternatives to developing new oral hypoglycemic agents, appropriate ethnobotanical information is scarce, obscure
and ambiguous.
Coccinia grandis (L.) Voigt. (Family: Cucurbitaceae) is a climbing perennial herb distributed almost all over
the world. The leaves of the plant possess antidiabetic, anti-inflammatory, antipyretic, analgesic, antispasmodic,
antimicrobial, cathartic and expectorant activities (Asolkar et al, 1992; Nadkami  and Nadkami, 1992).The leaves
contain Triterpenoids, alkaloids and tannins (Rastogi. and Mehrota, 1990). The objective of the present work is to
make an analysis of the ethnobotanical information on Coccinia grandis used in South Indian region for diabetes
mellitus control.
 
MATERIAL AND METHODS
Plant material and decoction preparation
            The leaves of C. grandis were collected in December 2007 from Coimbatore district, Tamilnadu, India and
authenticated by Botanical Survey of India (Southern circle), Coimbatore, Tamil Nadu, India. A voucher specimen is
being maintained in the RVS College of Arts and Science and RVS Medical & Ayurvedic foundation, Coimbatore.
The leaves were shade dried and powdered.
            About 150 g of dried powdered leaves were boiled in 1 liter of water for 5 min, allowing the decoction to
stand for 30 min and filtered through Whatman no.1 filter paper which yielded a decoction with a 15% higher
concentration than that of produced by the method described by Teixeira et al., (1990).
Test animals
            The test animals used in the study were procured from Karpagam Medical and Research Foundation.  Six
Albino rats of wistar strain weighing 150 - 200 g bred in Animal Tissue Culture Lab, Karpagam Arts and Science
College. They were individually housed in polypropylene cages in well-ventilated rooms, under hygienic conditions.
Animals were given water ad libitum and fed with rat pellet feed.
Induction of Experimental Diabetes and Treatment
            Alloxan monohydrate solution of 10 mg/ml was prepared in ice-cold citrate buffer 0.1 M, pH 4.5 and was
administered to the rats within 5 min at a dose of 50 mg/kg body weight intraperitonially. After 48 h of alloxan
monohydrate administration, rats with moderate diabetes having glycosuria and hyperglycemia were taken for the
experiment.
            Rats weighing 150 – 160 g, fasted over night were used for induction of diabetes. Rats were divided into two
sets; diabetic and non-diabetic. Group I received normal diet and served as normal control. Group II consists of
alloxan-induced rats receiving normal diet and serving as diabetic control. Group III consists of alloxan induced rats
receiving Gliben clamide (synthetic antidiabetic drug) at 0.5 mg/kg body weight once a day orally for 10 days.
Group IV consists of alloxan-induced rats receiving C. grandis (1 ml) once a day orally for 10 days. Group V
consists of normal rats receiving C. grandis (1 ml) once a day orally for 10 days.
            Blood samples were collected through the tail vein just prior to and on days 10 after drug administration. The
blood glucose, urea, cholesterol, serum glutamate oxygenate transaminase (SGOT) and serum glutamate pyruvate
transaminase (SGPT) were determined for all the samples.
Statistics
            The data were analyzed using one-way ANOVA followed by Dunnett's test. The level of significance was set
at 0.05.
 
RESULTS AND DISCUSSION
            The extracts of C. grandis produced significant changes in the alloxan-induced diabetic rats (Table 1). The
aqueous extracts of C. grandis reduced the glucose levels considerably. Treatment of the diabetic rats with Gliben
clamide (10 mg/kg) also reduced blood glucose level. The prolonged treatment of C. grandis extracts on alloxan-
induced diabetes rats produced consistent reduction in the blood glucose levels. The aqueous extract also reduced
urea, protein and cholesterol during the 10 days treatment period (Tables 1 and 2).
            It is possible that the drug may be acting by potentiating the pancreatic secreation or increasing the glucose
uptake. Hypercholesterolemia, hypertriglyceridemia and hyperurea have been reported to occur in alloxan diabetic
rats (Resmi et al., 2001; Joy and Kuttan, 1999). Increase in glycogen in liver can be brought about by an increase in
glycogenesis and/or decrease a glycogenolysis. Therefore, the C. grandis extract could have stimulated glycogenesis
and/or inhibited glycogenolysis in diabetic rat liver. The plant extracts treated animals showed non-toxicity of the
extract, which indicates that unlike insulin and other common hypoglycemic agents, overdose of the drug may not
result in hypoglycemia. The increase in total protein (Table 2) may be due to changes in circulating amino acids
levels, hepatic amino acids uptake, and muscle output of amino acid concentrations (Felig et al., 1977). The non-
protein nitrogen compound urea is found to be increased when compared to plant extract treated rats. The level of
SGPT and SGOT increased remarkably in the C. grandis extract-treated rats (Nagappa et al., 2003). Our results
support Ghosh et al., (2004) who reported that transaminase activity is increased in serum of diabetics. In diabetic
animals, the changes in level of serum enzymes are directly related to changes in the metabolism (Felig et al., 1977).
            C. grandis leaf extract showed significant anti-diabetic effect in diabetic rats after oral administration. Thus,
the claim made by the Indian systems of medicine regarding the use of leaf extract of this plant in the treatment of
diabetes is validated. Present efforts are directed to isolate the active constituents and elucidation of mechanism of
action.
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Table 1. Glucose and cholesterol content of serum of control and experimental rat groups.
 
Parameters
 
(Group I)
 
(Group II)
 
 (Group
III)
 
 (Group V)
 
 (Group V)
 
Glucose
(mg/dl)
114.71±
1.60
 
256.39±
7.22***
 
146.90 ±
1.76**
 
154.9±
14.3c***
 
160±
17.10.5d***
 
Cholesterol
(mg/dl)
120± 2.5
 
244.80±
6.28***
 
115±
3.40b***
 
112.2±
7.1c***
117±
5.9dNS
 
 
Table 2. The Concentrations of urea, total protein, SGOT and SGPT in serum of control and experimental groups.
Parameters
 
 (Group I)  (Group II)  (Group III)  (Group IV)  (Group V)
Urea (mg/dl)
 
44±2.8
 
 
61.5±5.0a***
 
56.0±5.0b***
 
88 ±3.2c***
 
50.0±2.8d**
 
SGOT (U/L)
 
23.3±1.2
 
 
24.2± 3.8a***
 
28.0±3.4b***
 
31.5±2.7c***
 
41.6±3.6d***
 
SGPT (U/L)
 
24.6±2.1
 
 
28.0±3.4a***
 
 
32.0±2.8b***
 
 
38.5±1.0c***
 
 
42.0±7.1d***
 
Total protein
(g/dl) 6.95±0.42 3.9±0.6a*** 2.4±0.5b*** 7.3±1.0c*** 7.9±0.8d*
 
Values are taken as mean of five individual’s experiments and expressed as
Mean ± S.D.
***p< 0.001, **p< 0.01 and *p< 0.05. NS = Not Significant.
 
Group I & II   - Normal and Diabetic control
Group III        - Diabetic treated with Synthetic drug
Group IV        - Diabetic treated with Plant drug
Group V          - Plant drug
 
 
 
